Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ121712190,33
KB101910200,59
PKN85,4585,48-2,29
Msft505,02505,7-0,06
Nokia4,134,1341,32
IBM281,23282,86-0,04
Mercedes-Benz Group AG52,2752,31,34
PFE24,6724,680,28
17.07.2025 12:23:23
Indexy online
AD Index online
select
AD Index online
 

  • 17.07.2025 12:10:45
Futura Medical (FUM.L, London)
Poslední obchod Změna (%) Změna (GBP) Objem obchodů (GBP)
0,097 -3,48 0,00 5 873
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 17.07.2025
Popis společnosti
Obecné informace
Název společnostiFutura Medical PLC
TickerFUM
Kmenové akcie:Ordinary Shares
RICFUM.L
ISINGB0033278473
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.12.2024
Počet zaměstnanců k 31.12.2023 12
Akcie v oběhu k 17.06.2025 303 703 568
MěnaGBP
Kontaktní informace
Ulice40 Occam Road
MěstoGUILDFORD
PSČGU2 7YG
ZeměUnited Kingdom
Kontatní osoba 
Funkce kontaktní osoby 
Telefon441 483 685 670
Fax441483685671

Business Summary: Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Futura Medical PLC revenues increased from L3.1M to L13.9M. Net income totaled L1.3M vs. loss of L6.5M. Revenues reflect EU and UK segment increase of 75% to L4.8M, Rest of the world (Region) segment increase from L375K to L1.3M. Net Income reflects Development and commercialisation segment income totaling L1.2M vs. loss of L7M.
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 17.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Finance Director, Chief Operating Officer, Company Secretary, Executive DirectorAngela Hildreth-
Executive Director, Head of R&DKen James6916.11.201616.11.2016